Trial Review

Registering a new trial?

To achieve prospective registration, we recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT05104463




Registration number
NCT05104463
Ethics application status
Date submitted
20/10/2021
Date registered
3/11/2021
Date last updated
22/02/2024

Titles & IDs
Public title
A Study of CST-2032 and CST-107 in Subjects With Mild Cognitive Impairment or Mild Dementia Due to Parkinson's or Alzheimer's Disease
Scientific title
A Phase 2a, Randomized, Placebo-Controlled, Double-Blind, Crossover Study to Evaluate the Effects of CST-2032 and CST-107 on Cognition in Subjects With Mild Cognitive Impairment or Mild Dementia Due to Parkinson's or Alzheimer's Disease
Secondary ID [1] 0 0
CST2032/CST107-CLIN-015
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Mild Cognitive Impairment 0 0
Dementia 0 0
Condition category
Condition code
Neurological 0 0 0 0
Alzheimer's disease
Neurological 0 0 0 0
Dementias
Mental Health 0 0 0 0
Other mental health disorders

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - CST-2032, matching placebo for CST-2032, CST-107, matching placebo for CST-107

Experimental: CST-2032 (3mg)/CST-107 (3mg) to Placebo - Subjects will receive daily doses of CST-2032 (3mg) co-administered with CST-107 (3mg) for 14 days, followed by a washout period of no drug for 7 days, followed by matching placebo for CST-2032 and matching placebo for CST-107 for 14 days.

Experimental: Placebo to CST-2032 (3mg)/CST-107 (3mg) - Subjects will receive matching placebo for CST-2032 and matching placebo for CST-107 for 14 days followed by a washout period of no drug for 7 days, followed by daily doses of CST-2032 (3mg) co-administered with CST-107 (3mg) for 14 days.

Experimental: CST-2032 (6mg)/CST-107 (3mg) to Placebo - Subjects will receive daily doses of CST-2032 (6mg) co-administered with CST-107 (3mg) for 14 days, followed by a washout period of no drug for 7 days, followed by matching placebo for CST-2032 and matching placebo for CST-107 for 14 days.

Experimental: Placebo to CST-2032 (6mg)/CST-107 (3mg) - Subjects will receive matching placebo for CST-2032 and matching placebo for CST-107 for 14 days followed by a washout period of no drug for 7 days, followed by daily doses of CST-2032 (6mg) co-administered with CST-107 (3mg) for 14 days.


Treatment: Drugs: CST-2032, matching placebo for CST-2032, CST-107, matching placebo for CST-107
CST-2032 and matching placebo white tablets, CST-107 and matching placebo yellow tablets
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Treatment-emergent adverse events
Timepoint [1] 0 0
Change from Baseline after 14 days of treatment
Primary outcome [2] 0 0
Vital Signs
Timepoint [2] 0 0
Change from Baseline after 14 days of treatment
Primary outcome [3] 0 0
Electrocardiograms (ECGs)
Timepoint [3] 0 0
Change from Baseline after 14 days of treatment
Secondary outcome [1] 0 0
Change from Baseline in CANTAB Reaction Time Task
Timepoint [1] 0 0
Change from Baseline after 14 days of treatment
Secondary outcome [2] 0 0
Change from Baseline in CANTAB Rapid Visual Information Processing
Timepoint [2] 0 0
Change from Baseline after 14 days of treatment
Secondary outcome [3] 0 0
Change from Baseline in CANTAB Verbal Recognition Memory
Timepoint [3] 0 0
Change from Baseline after 14 days of treatment
Secondary outcome [4] 0 0
Change from Baseline in CANTAB Adaptive Tracking Task
Timepoint [4] 0 0
Change from Baseline after 14 days of treatment
Secondary outcome [5] 0 0
Change from Baseline in CANTAB Paired Associates Learning Test
Timepoint [5] 0 0
Change from Baseline after 14 days of treatment
Secondary outcome [6] 0 0
Change from Baseline in CANTAB Stop Signal Task
Timepoint [6] 0 0
Change from Baseline after 14 days of treatment
Secondary outcome [7] 0 0
Change from Baseline in Negative Emotional Bias in the Facial Expression Recognition Task (FERT)
Timepoint [7] 0 0
Change from Baseline after 14 days of treatment

Eligibility
Key inclusion criteria
* Male or female subjects = 50 and = 85 years of age at time of informed consent.
* Diagnosis of mild cognitive impairment OR mild dementia due to either: Parkinson's disease associated with REM sleep behavior disorder (RBD+PD) and positive response to the RBD Single-Question Screen (RBD1Q) and without hallucinations; OR Alzheimer's Disease (AD).
* For subjects taking anti-Parkinsonian medication: stable daily dosing for at least 1 month prior to Screening and through the End of Study
* If the subject is taking a single drug for AD (e.g., donepezil or other cholinesterase inhibitors or memantine; dual therapy is excluded), they must have been on a stable dose for at least 2 months prior to Day 1, and the dose must remain unchanged during the study unless required for management of adverse events (AEs).
* Cognitive decline not primarily caused by traumatic, or medical problems (alternative causes of cognitive decline are ruled out).
* Adequate visual and auditory abilities to perform all aspects of the cognitive and functional assessments.
* Has a spouse or caregiver who can accompany the subject at specified study visits (if required based on cognitive function).
* A score of greater than or equal to one standard deviation below age and educational norms in the Digit Symbol Substitution Test (DSST) during screening or within 6 months prior to Screening.
* Montreal Cognitive Assessment (MoCA) score = 18 and = 26.
* Adaptive criteria for enrollment based on the locus ceruleus (LC) neuromelanin sensitive magnetic resonance imaging (NM-MRI) contrast-to-noise ratio (CNR).
* Unless confirmed to be azoospermic (vasectomized or secondary to medical cause), males must agree to use a male condom from Day 1 until the follow-up visit when having penile-vaginal intercourse with a woman of childbearing potential who is not currently pregnant. Note: Men with a pregnant or breastfeeding partner must agree to remain abstinent from penile-vaginal intercourse or use a condom during each episode of penile-vaginal penetration until after the Follow-Up Visit.
* Females of childbearing potential (i.e., not postmenopausal or surgically sterile) who have a male partner must have a negative serum pregnancy test result and must agree to one of the following from start of Screening through 30 days after the last study medication administration: use a highly effective method of birth control; or monogamous relationship with a male partner of confirmed sterility; or practice complete abstinence.
* Females of non-childbearing potential may be enrolled if it is documented that they are postmenopausal.
* Body weight greater or equal to 50 kg and body mass index (BMI) between 18 and 35 kg/m2, inclusive at Screening.
* Stable medical conditions for 3 months prior to Screening visit (e.g., controlled hypertension, dyslipidemia).
* Willing to follow the protocol requirements and comply with protocol restrictions.
* Capable of providing informed consent and complying with study procedures.
Minimum age
50 Years
Maximum age
85 Years
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
* Subjects with poorly controlled hypertension despite lifestyle modifications and/or pharmacotherapy.
* Subjects with pulmonary disease, including asthma if requiring the use of a ß2-adrenergic bronchodilator, or evidence of clinically significant moderate or severe pulmonary symptoms.
* Clinical signs indicating syndromes such as corticobasal degeneration, supranuclear gaze palsy, multiple system atrophy, chronic traumatic encephalopathy, signs of frontotemporal dementia, history of stroke, head injury or encephalitis, cerebellar signs, early severe autonomic involvement, or Babinski sign.
* Current evidence or history in the past two years of: epilepsy, focal brain lesion, head injury with loss of consciousness or meeting DSM-V diagnostic criteria for psychotic disorders, such as schizophrenia or bipolar disorder, or have unstable concomitant psychiatric symptomatology except for depressed mood.
* Evidence of any significant clinical disorder or laboratory finding that renders the participant unsuitable for receiving an investigational drug including clinically significant or unstable hematologic, hepatic, cardiovascular, pulmonary, gastrointestinal, endocrine (including thyrotoxicosis, excluding managed hypo and hyperthyroidism), metabolic, renal, or other systemic disease or laboratory abnormality.
* History of malignant disease within 5 years, including solid tumors and hematologic malignancies (except basal cell and squamous cell carcinomas of the skin that have been completely excised and are considered cured).
* Any clinically significant illness or disease as determined by medical and surgical history, physical examination, 12-lead electrocardiogram (ECG) and clinical laboratory assessments conducted at Screening.
* Clinically significant abnormalities of ECG, including QTcF > 450 ms, for males and QTcF > 470 ms for females, and/or HR < 50 beats per minute, or evidence of clinically significant bundle branch blocks, as indicated by 12-lead ECG during the Screening Period.
* A calculated creatinine clearance of =60 mL/min according to the Cockcroft-Gault equation.
* Current use of any prohibited prescription medication, over-the-counter medication, or herbal supplements including green tea/products during Screening or throughout study, unless approved by both the Investigator and the Sponsor Medical Monitor.
* Prior treatment with any investigational drug =90 days prior to dosing (Day 1), or =5 half-lives of the drug (whichever is longer), or current enrollment in any other study treatment or disease study, except for observational studies.
* Known or suspected alcohol or substance abuse within the past 12 months and/or positive test for alcohol or drugs of abuse at Screening or Day 1.
* Suicidal ideation with actual intent or plan ("Yes" answer on the C-SSRS ideation items 4 or 5) within 3 months prior to study Screening.
* Positive screening test for hepatitis C antibody (HCV Ab) or current hepatitis B infection (defined as positive for hepatitis B surface antigen [HBsAg] at Screening). Subjects with immunity to hepatitis B (defined as negative HbsAg and positive hepatitis B surface antibody [HbsAb]) are eligible to participate in the study.
* Positive screening test for human immunodeficiency virus (HIV).
* Current infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
* Females who are breastfeeding.
* Any other reason for which the PI considers it is not in the best interest of the participant to undertake the study.

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Intervention assignment
Crossover
Other design features
Phase
Phase 2
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
12/04/2022
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
1/02/2024
Sample size
Target
Accrual to date
Final
64
Recruitment in Australia
Recruitment state(s)
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Arizona
Country [2] 0 0
United States of America
State/province [2] 0 0
California
Country [3] 0 0
United States of America
State/province [3] 0 0
Florida
Country [4] 0 0
United States of America
State/province [4] 0 0
New York
Country [5] 0 0
United States of America
State/province [5] 0 0
Ohio
Country [6] 0 0
United States of America
State/province [6] 0 0
Texas
Country [7] 0 0
United States of America
State/province [7] 0 0
Utah
Country [8] 0 0
New Zealand
State/province [8] 0 0
Christchurch

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
CuraSen Therapeutics, Inc.
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
This is a Phase 2a, randomized, placebo-controlled, double-blind, crossover study to evaluate the effects CST-2032 administered with CST-107 on cognition in subjects with Mild Cognitive Impairment (MCI) or mild dementia.
Trial website
https://clinicaltrials.gov/study/NCT05104463
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Chief Medical Officer
Address 0 0
CuraSen Therapeutics, Inc.
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/study/NCT05104463